A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data.
Saved in:
| Title: | A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data. |
|---|---|
| Authors: | Irving, Adam1,2 (AUTHOR) adam.irving@monash.edu, Petrie, Dennis1 (AUTHOR), Harris, Anthony1 (AUTHOR), Fanning, Laura1,2 (AUTHOR), Wood, Erica M.2 (AUTHOR), Moore, Elizabeth2 (AUTHOR), Wellard, Cameron2 (AUTHOR), Waters, Neil2 (AUTHOR), Augustson, Bradley3 (AUTHOR), Cook, Gordon4 (AUTHOR), Gay, Francesca5 (AUTHOR), McCaughan, Georgia6,7 (AUTHOR), Mollee, Peter8 (AUTHOR), Spencer, Andrew9 (AUTHOR), McQuilten, Zoe K.2 (AUTHOR) |
| Source: | PharmacoEconomics. Jan2026, Vol. 44 Issue 1, p83-95. 13p. |
| Database: | Business Source Ultimate |
| ISSN: | 11707690 |
|---|---|
| DOI: | 10.1007/s40273-025-01554-4 |
